SML2746
SRS11-92
≥98% (HPLC)
Synonym(s):
4-(Cyclohexylamino)-3-[(phenylmethyl)amino]-benzoic acid ethyl ester, Ethyl 3-(benzylamino)-4-(cyclohexylamino)benzoate
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Recommended Products
Quality Level
assay
≥98% (HPLC)
form
powder
color
white to yellow-brown
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
Biochem/physiol Actions
SRS11-92 is a cell penetrant and potent inhibitor of ferroptosis that attenuates the cell death associated with frataxin knockdown in healthy human fibroblasts. SRS11-92 protects against cell death in in a brain slice model of Huntington′s disease, an oligodendrocyte model of periventricular leukomalacia, and in isolated kidney proximal tubules model of kidney disfunction.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Journal of medicinal chemistry, 59(5), 2041-2053 (2015-12-24)
Ferroptosis is a nonapoptotic, iron-catalyzed form of regulated necrosis that is critically dependent on glutathione peroxidase 4 (GPX4). It has been shown to contribute to liver and kidney ischemia reperfusion injury in mice. A chemical inhibitor discovered by high-throughput screening
Journal of the American Chemical Society, 136(12), 4551-4556 (2014-03-07)
Ferrostatin-1 (Fer-1) inhibits ferroptosis, a form of regulated, oxidative, nonapoptotic cell death. We found that Fer-1 inhibited cell death in cellular models of Huntington's disease (HD), periventricular leukomalacia (PVL), and kidney dysfunction; Fer-1 inhibited lipid peroxidation, but not mitochondrial reactive
The Journal of pharmacology and experimental therapeutics, 369(1), 47-54 (2019-01-13)
Friedreich ataxia (FRDA) is a progressive neuro- and cardio-degenerative disorder characterized by ataxia, sensory loss, and hypertrophic cardiomyopathy. In most cases, the disorder is caused by GAA repeat expansions in the first introns of both alleles of the FXN gene
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service